Medytox said on the 10th that its operating profit on a consolidation basis for the third quarter of this year was 8.9 billion won, up 48.3% from the same period a year earlier, based on preliminary figures. Revenue for the same period also rose 13.3% year over year to 61 billion won.
The company also posted a net profit for the period of 7.2 billion won, up 90.5%, surpassing 60 billion won in quarterly revenue for three consecutive quarters.
In particular, revenue in the botulinum toxin preparation institutional sector, the main business, showed strong growth of 38% year over year, driving solid results. The global market entry of Numeco's next-generation botulinum toxin preparation "Newlux" proved effective. Newlux is expanding overseas registrations in Asia, Europe and South America. The hyaluronic acid (HA) filler "Neuramis" is also on a rising sales trend.
The company projected that once the next-generation fat-dissolving injectable "Newvú" and its independently developed body fat reduction probiotics are fully launched in the market in the first half of next year, revenue growth will accelerate further. It is also preparing to file for U.S. Food and Drug Administration (FDA) approval of the non-animal liquid-type botulinum toxin preparation "MT10109L."
A Medytox official said, "Botulinum toxin sales grew evenly in both domestic and overseas markets, underpinning solid performance," and added, "We will further secure growth drivers with Newvú and the body fat reduction probiotic health functional food 'MT961,' which we aim to launch next year."